secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001104659-23-044043
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma appoints James C. Kelly as Class I director
----------------------------------------------------------------

- James C. Kelly appointed to Board on April 11, 2023, as Class I director through 2024 AGM.
- Kelly is Managing Director at Weiss Asset Management, joined in 2010.
- He waived equity component of director compensation; standard indemnification agreement in place.
- Board size increased to 10, will revert to 9 after Annual Meeting; Kelly deemed independent.
- As of March 6, 2023, Kelly beneficially owned 0 ordinary shares of Theravance Biopharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923044043/0001104659-23-044043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923044043/tm2312299d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-044043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer